Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase for TLS Prevention During Two Chemotherapy Cycles
NCT01200485Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2011
- Primary completion
- Jul 2016
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rasburicase in tumor lysis syndrome (TLS), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2011; status: completed.
02
Drugs
rasburicase
03
Conditions
tumor lysis syndrome (TLS)
Beyond the preview
Go deeper on NCT01200485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01200485.